Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 16/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000868 | 0.88 | CYP4F2 (0.64) | CYP4F2CYP4A11FFAR1SLC5A1SLC5A2 | |
| SCHEMBL16254172 | 0.85 | ACACB (0.68) | ACACBSLC5A1SLC5A2 | |
| SCHEMBL456459 | 0.85 | FFAR1 (0.67) | ACACBFFAR1 | |
| SCHEMBL12401878 | 0.84 | CYP4F2 (0.68) | CYP4F2CYP4A11SLC5A1SLC5A2 | |
| SCHEMBL68902 | 0.82 | CYP4F2 (0.85) | CYP4F2CYP4A11 | |
| SCHEMBL12548347 | 0.82 | CYP4Z1 (0.58) | CYP4F2CYP4A11SLC5A1SLC5A2 | |
| SCHEMBL11969671 | 0.81 | ACACB (0.65) | ACACB | |
| SCHEMBL16695953 | 0.81 | CYP4F2 (0.62) | CYP4F2CYP4A11FFAR1 | |
| SCHEMBL16972780 | 0.81 | CYP4F2 (0.62) | CYP4F2CYP4A11FFAR1SLC5A1SLC5A2 | |
| SCHEMBL1551072 | 0.80 | CYP4F2 (0.66) | CYP4F2CYP4A11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614054-B1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8877754-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877754-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877754-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2614054-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012032014-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885CYP4F2 246/4885CYP4A11 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.